Anti-interleukin-13 antibody therapy for asthma: one step closer.
نویسنده
چکیده
C urrent guidelines for the treatment of asthma recommend inhaled corticosteroids for all patients with persistent asthma. Despite the increasing use of these drugs, asthma remains poorly controlled in a small subset of individuals who do not respond fully to existing therapies. The medical needs of these patients have prompted a search for new medications that inhibit specific molecular targets thought to play key roles in asthma pathogenesis.
منابع مشابه
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
Human eosinophils represent approximately 1% of peripheral blood leukocytes. However, these cells have the propensity to leave the blood stream and migrate into inflamed tissues. Eosinophilic inflammation is present in a significant proportion of patients with severe asthma. Asthma is a chronic inflammatory disorder that affects more than 315 million people worldwide, with 10% having severe unc...
متن کاملRPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study
INTRODUCTION A unique anti-interleukin (IL)-13 monoclonal antibody, RPC4046, was generated on the basis of differential IL-13 receptor (R) blockade as assessed in a murine asthma model; the safety, tolerability, pharmacokinetics, and pharmacodynamics of RPC4046 were evaluated in a first-in-human study. METHODS Anti-IL-13 antibodies with varying receptor blocking specificity were evaluated in ...
متن کاملInvestigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma.
Asthma is a complex, persistent, inflammatory disease characterised by airway hyperresponsiveness in association with airway inflammation. Studies suggest that regular use of high-dose inhaled corticosteroids and long-acting bronchodilators or omalizumab (a humanised monoclonal antibody that binds to immunoglobulin E and is often used as next-step therapy) may not be sufficient to provide asthm...
متن کاملHumanized Anti-IL-5 Antibody Therapy
Eosinophils are suppressed by a new class of drugs targeting Interleukin-5 (IL-5), an eosinophil growth, activation, and survival factor. Humanized anti-IL-5 antibodies are effective in treating asthma patients with the severe eosinophilic form of the disease and are the first new class of asthma drugs approved in 12 years.
متن کاملEvaluation of Serum Interleukin-18 levels in Helicobacter Pylori-infected Peptic Ulcer Patients and its Association with Bacterial CagA Virulence Factor
Background: Helicobacter pylori infection is one of the most common gastrointestinal infections worldwide. Predominant T-helper 1 (Th1) responses with increased gamma interferon (IFN- γ) levels have been proposed to play an important role in H. pylori-induced peptic ulcer. However, bacterial factors contributing to the initiation of Th1 polarization of H. pylori-specific immune responses have n...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The European respiratory journal
دوره 41 2 شماره
صفحات -
تاریخ انتشار 2013